Clinical trial · Interventional
Preference Study With Elderly Patients Recurrent Ovarian Cancer
Präferenz-Studie Bei älteren Patientinnen Mit Ovarialkarzinomrezidiv: Treosulfan Oral vs. intravenös
NCT00170690CI-TRIAL-00010516completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Treosulfan | Drug | Treosulfan | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
- interventionNames
- Drug: Treosulfan
- type
- EXPERIMENTAL
- label
- 2
- description
- Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
- interventionNames
- Drug: Treosulfan
Primary outcomes (1)
- measure
- Comparison of patient´s compliance in both arms defined as therapy break-offs
- timeFrame
- during study treatment
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patient with relapsed ovarian cancer * study therapy of third regime * measurable or evaluable tumor lesions or progression defined as CA-125 more than \>= 100 U/ ml. * Age \>= 70 years * ECOG 0-2 * written informed consent Exclusion Criteria: * Pretreatment with treosulfan * patient without measurable or evaluable tumor lesions or CA-125 more than \>= 100 U/ ml. * no adequate bone marrow function (leukocyte \<= 2,9 x 109/l, platelets \<= 100 x 109/ l * creatinin and bilirubin within \>= 1,25 x fold of the reference laboratory´s normal range * simultaneous radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.